<DOC>
	<DOCNO>NCT01932229</DOCNO>
	<brief_summary>Advanced lung cancer ( non-small cell lung cancer ) mutation EGFR ( epidermal growth factor receptor ) gene , disease progression treatment EGFR inhibitor ( erlotinib gefitinib ) , progression disease also treatment chemotherapy recruit . The trial one arm , afatinib daily treatment . Blood exhale breath sample collect investigation aim identify factor predict response afatinib .</brief_summary>
	<brief_title>An Open Label Study BIBW 2992/Afatinib Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib Gefitinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Advanced NSCLC EGFR mutation six month longer benefit EGFR TKIs Disease progression chemotherapy , inability receive chemotherapy medical reason . Disease progression EGFR TKI , presence EGFR mutation predict poor response first generation EGFR TKIs . Inability take oral drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Advanced NSCLC</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>TKIs</keyword>
	<keyword>Tyrosine Kinase Inhibitors</keyword>
</DOC>